BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y, Pachkoria K, García-Cortés M, Fernández MC, Pelaez G, Rodrigo L, Durán JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Muņoz-Yagüe T, Salmerón J, Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006;44:1581-8. [PMID: 17133470 DOI: 10.1002/hep.21424] [Cited by in Crossref: 197] [Cited by in F6Publishing: 167] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Teschke R, Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol 2018;84:1467-77. [PMID: 29607530 DOI: 10.1111/bcp.13593] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
2 Papay J. Response to Letter to the editor by Papay Regulatory Toxicology and Pharmacology 54 (2009), pp. 84–90 Drug-Induced Liver Injury Following Positive Drug Rechallenge. Regulatory Toxicology and Pharmacology 2009;54:314. [DOI: 10.1016/j.yrtph.2009.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Stocco G, Lucafò M, Decorti G. Pharmacogenomics of Antibiotics. Int J Mol Sci 2020;21:E5975. [PMID: 32825180 DOI: 10.3390/ijms21175975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hernandez N, Pontet Y, Bessone F. Translating new knowledge on drug-induced liver injury into clinical practice. Frontline Gastroenterol 2020;11:303-10. [PMID: 32587673 DOI: 10.1136/flgastro-2018-101120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 García-aparicio J, Herrero-herrero J. Hepatitis tóxica tras tratamiento secuencial con cotrimoxazol, levofloxacino, doxiciclina y sertralina en paciente con infección respiratoria. Farmacia Hospitalaria 2010;34:152-4. [DOI: 10.1016/j.farma.2009.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 García-Cortés M, Ortega-Alonso A, Lucena MI, Andrade RJ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos GEHAM).l. Drug-induced liver injury: a safety review. Expert Opin Drug Saf 2018;17:795-804. [PMID: 30059261 DOI: 10.1080/14740338.2018.1505861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
7 Andrade RJ, López-Ortega S, López-Vega MC, Robles M, Cueto I, Lucena MI. Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Rev Clin Pharmacol 2008;1:261-76. [PMID: 24422651 DOI: 10.1586/17512433.1.2.261] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
8 Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int. 2019;39:31-41. [PMID: 30003672 DOI: 10.1111/liv.13931] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
9 Sridharan K, Daylami AA, Ajjawi R, Ajooz HAMA. Drug-Induced Liver Injury in Critically Ill Children Taking Antiepileptic Drugs: A Retrospective Study. Curr Ther Res Clin Exp 2020;92:100580. [PMID: 32280391 DOI: 10.1016/j.curtheres.2020.100580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
10 Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50:511-517. [PMID: 19155082 DOI: 10.1016/j.jhep.2008.10.021] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 7.5] [Reference Citation Analysis]
11 Naisbitt DJ, Olsson-Brown A, Gibson A, Meng X, Ogese MO, Tailor A, Thomson P. Immune dysregulation increases the incidence of delayed-type drug hypersensitivity reactions. Allergy 2020;75:781-97. [PMID: 31758810 DOI: 10.1111/all.14127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
12 Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review. Liver Int. 2015;35:2343-2353. [PMID: 26346512 DOI: 10.1111/liv.12958] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
13 Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jimenez A, Ulzurrun E, Gonzalez AF, Fernandez MC, Romero-Gómez M. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147:109-118.e5. [PMID: 24704526 DOI: 10.1053/j.gastro.2014.03.050] [Cited by in Crossref: 161] [Cited by in F6Publishing: 145] [Article Influence: 23.0] [Reference Citation Analysis]
14 Wu SL, Cheng CN, Wang CC, Lin SW, Kuo CH. Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Toxicol Appl Pharmacol 2020;403:115157. [PMID: 32717240 DOI: 10.1016/j.taap.2020.115157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Crespo Pérez L, Moreira Vicente V, Manzano Fernández R, García Aguilera XA. Colestasis asociada a tratamiento con pregabalina. Medicina Clínica 2008;130:157-8. [DOI: 10.1157/13115781] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
16 Teschke R, Danan G. Causality Assessment Methods in Drug-Induced Liver Injury. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 555-94. [DOI: 10.1007/978-1-4939-7677-5_27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
17 Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy’s law. Gastroenterology. 2014;147:20-24. [PMID: 24880009 DOI: 10.1053/j.gastro.2014.05.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
18 Hayashi PH, Bjornsson ES. Long-Term Outcomes After Drug-Induced Liver Injury. Curr Hepatol Rep 2018;17:292-9. [PMID: 30666283 DOI: 10.1007/s11901-018-0411-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
19 Stephens C, Robles-diaz M, Medina-caliz I, Garcia-cortes M, Ortega-alonso A, Sanabria-cabrera J, Gonzalez-jimenez A, Alvarez-alvarez I, Slim M, Jimenez-perez M, Gonzalez-grande R, Fernández MC, Casado M, Soriano G, Román E, Hallal H, Romero-gomez M, Castiella A, Conde I, Prieto M, Moreno-planas JM, Giraldez A, Moreno-sanfiel JM, Kaplowitz N, Lucena MI, Andrade RJ, Andrade R, Lucena M, Stephens C, Cortés MG, Robles-díaz M, Ortega-alonso A, Pinazo J, Muñoz BG, Alcántara R, Hernández A, Escaño MG, del Campo E, Medina-cáliz I, Sanabria-cabrera J, González-jiménez A, Sanjuán-jiménez R, Cueto A, Álvarez-álvarez I, Bonilla E, Di Zeo D, Niu H, Villanueva M, Papineau A, Pérez MJ, Grande RG, Ortega SL, Santaella I, Ocaña A, Palomino P, Fernández M, Peláez G, Porcel A, Casado M, Sánchez MG, Romero-gómez M, Millán-domínguez R, Fombuena B, Gallego R, Ampuero J, Campo JD, Calle-sanz R, Rojas L, Rojas A, Gómez AG, Vilar E, Soriano G, Guarner C, Román E, Manuitt MQ, Arbos RA, Delgado JS, Gómez MV, Hallal H, Oltra EG, Arcos JT, Martínez AP, Cobarro CS, Caparrós JE, Castiella A, Zapata E, Arenas J, García AG, Esandi F, Blanco S, Odriozola PM, Crespo J, Iruzubieta P, Cabezas J, Gallego AG, Rodríguez Seguel EDP, Cuaresma M, Gallego JG, Jorquera F, Campos SS, Otazua P, de Juan Gómez A, Salmerón J, Gila A, Quiles R, González J, Lorenzo S, Prieto M, Amiel IC, Berenguer M, García-eliz M, Primo J, Molés J, Garayoa A, Carrascosa M, Domínguez EG, Cuevas L, Farré M, Montané E, Barriocanal A, Arellano A, Sanz Y, Morillas R, Sala M, Ridaura HM, Bruguera M, Gines P, Lens S, García J, Mariño Z, Guerra MH, Sanfiel JM, Fernández del Campo CB, Tejedor M, Ferrer RG, Fernández C, Gil MF, Montero J, Mata MDL, Olmo JF, Bonilla EF, Moreno J, Martínez-rodenas P, Garrido M, Oliva C, Rendón P, Samaniego JG, Madejón A, Calleja J, Porras JM, Cabriada J, Pérez-moreno J, Lara C. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. Journal of Hepatology 2021;75:86-97. [DOI: 10.1016/j.jhep.2021.01.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
20 Tian Q, Yang R, Wang Y, Liu J, Wee A, Saxena R, Wang L, Li M, Liu L, Shan S, Kong Y, Ma H, Ou X, You H, Zhao X, Jia J. A High Serum Level of Taurocholic Acid Is Correlated With the Severity and Resolution of Drug-induced Liver Injury. Clin Gastroenterol Hepatol 2021;19:1009-1019.e11. [PMID: 32634627 DOI: 10.1016/j.cgh.2020.06.067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016;10:517-536. [PMID: 26633044 DOI: 10.1586/17474124.2016.1127756] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
22 Ashby K, Zhuang W, González-Jimenez A, Alvarez-Alvarez I, Lucena MI, Andrade RJ, Aithal GP, Suzuki A, Chen M. Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. J Hepatol 2021;75:333-41. [PMID: 33845060 DOI: 10.1016/j.jhep.2021.03.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6:673-684. [PMID: 17967156 DOI: 10.1517/14740338.6.6.673] [Cited by in Crossref: 121] [Cited by in F6Publishing: 101] [Article Influence: 8.6] [Reference Citation Analysis]
24 Iruzubieta P, Arias-Loste MT, Barbier-Torres L, Martinez-Chantar ML, Crespo J. The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? Biomed Res Int 2015;2015:386186. [PMID: 26824035 DOI: 10.1155/2015/386186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
25 Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011;66:1431-1446. [PMID: 21586591 DOI: 10.1093/jac/dkr159] [Cited by in Crossref: 93] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
26 Morii K, Nishisaka M, Nakamura S, Oda T, Aoyama Y, Yamamoto T, Kishida H, Okushin H, Uesaka K. A case of synthetic oestrogen-induced autoimmune hepatitis with microvesicular steatosis. J Clin Pharm Ther 2014;39:573-6. [DOI: 10.1111/jcpt.12191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55-68. [PMID: 19132805 DOI: 10.2165/00002018-200932010-00005.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Kaplowitz N. Dealing with stress. Hepatology 2012;55:3-13. [PMID: 22135222 DOI: 10.1002/hep.25515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Marin Zuluaga JI, Marin Castro AE, Perez Cadavid JC, Restrepo Gutierrez JC. Albendazole-induced granulomatous hepatitis: a case report. J Med Case Rep 2013;7:201. [PMID: 23889970 DOI: 10.1186/1752-1947-7-201] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
30 Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, Fontana RJ, Hayashi PH. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117-2126. [PMID: 20512999 DOI: 10.1002/hep.23577] [Cited by in Crossref: 233] [Cited by in F6Publishing: 195] [Article Influence: 21.2] [Reference Citation Analysis]
31 Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3-13. [PMID: 20374223 DOI: 10.1111/j.1365-2036.2010.04320.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 7.6] [Reference Citation Analysis]
32 Li LM, Wang D, Zen K. MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol. 2014;2:162-169. [PMID: 26357624 DOI: 10.14218/jcth.2014.00015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
33 Sarges P, Steinberg JM, Lewis JH. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Saf 2016;39:801-21. [DOI: 10.1007/s40264-016-0427-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
34 Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, Stephens C, Ortega-Alonso A, Garcia-Cortes M, González-Jimenez A, Sanabria-Cabrera JA, Moreno I, Fernandez MC, Romero-Gomez M, Navarro JM, Barriocanal AM, Montane E, Hallal H, Blanco S, Soriano G, Roman EM, Gómez-Dominguez E, Castiella A, Zapata EM, Jimenez-Perez M, Moreno JM, Aldea-Perona A, Hernández-Guerra M, Prieto M, Zoubek ME, Kaplowitz N, Lucena MI, Andrade RJ; Spanish DILI registry. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury.J Hepatol. 2016;65:532-542. [PMID: 27184533 DOI: 10.1016/j.jhep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 14.4] [Reference Citation Analysis]
35 Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis. 2013;17:191-209. [PMID: 23540497 DOI: 10.1016/j.cld.2012.11.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
36 Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol Drug Saf. 2011;20:567-582. [PMID: 21702069 DOI: 10.1002/pds.2127] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
37 Chaudhry M, Maqsood A, Diab-agha S, Rosenberg J. Nicardipine-Induced Acute Hepatitis in an Intensive Care Unit Patient. American Journal of Therapeutics 2009;16:71-3. [DOI: 10.1097/mjt.0b013e31817fde68] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
38 Panahi L, Surani SS, Udeani G, Patel NP, Sellers J. Hepatotoxicity Secondary to Levofloxacin Use. Cureus 2021;13:e15973. [PMID: 34336465 DOI: 10.7759/cureus.15973] [Reference Citation Analysis]
39 European Association for the Study of the Liver;  Clinical Practice Guideline Panel: Chair;  Panel members;  EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70:1222-1261. [PMID: 30926241 DOI: 10.1016/j.jhep.2019.02.014] [Cited by in Crossref: 198] [Cited by in F6Publishing: 155] [Article Influence: 99.0] [Reference Citation Analysis]
40 Agúndez JA, Lucena MI, Martínez C, Andrade RJ, Blanca M, Ayuso P, García-Martín E. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2011;7:817-828. [PMID: 21473713 DOI: 10.1517/17425255.2011.574613] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
41 Watkins PB. Biomarkers for drug-induced liver injury. Therapy 2010;7:367-75. [DOI: 10.2217/thy.10.10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
42 García-cortés M, Stephens C, Lucena MI, Fernández-castañer A, Andrade RJ. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. Journal of Hepatology 2011;55:683-91. [DOI: 10.1016/j.jhep.2011.02.007] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 11.7] [Reference Citation Analysis]
43 Ortega-Alonso A, Andrade RJ. Chronic liver injury induced by drugs and toxins. J Dig Dis 2018;19:514-21. [PMID: 29808546 DOI: 10.1111/1751-2980.12612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
44 Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 2017;37:173-8. [DOI: 10.1111/liv.13308] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 9.6] [Reference Citation Analysis]
45 Teschke R, Wolff A. Kava hepatotoxicity: Regulatory data selection and causality assessment. Digestive and Liver Disease 2009;41:891-901. [DOI: 10.1016/j.dld.2009.04.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
46 Björnsson ES, Andrade RJ. Long-term sequelae of Drug-induced liver injury. J Hepatol 2021:S0168-8278(21)02118-8. [PMID: 34688732 DOI: 10.1016/j.jhep.2021.10.011] [Reference Citation Analysis]
47 Lee SJ, Lee YJ, Park KK. The pathogenesis of drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2016;10:1175-85. [PMID: 27248313 DOI: 10.1080/17474124.2016.1196133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
48 Khoury T, Rmeileh AA, Yosha L, Benson AA, Daher S, Mizrahi M. Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol 2015;3:99-108. [PMID: 26356634 DOI: 10.14218/JCTH.2015.00007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
49 Kleiner DE. Histopathological challenges in suspected drug-induced liver injury. Liver Int 2018;38:198-209. [PMID: 28865179 DOI: 10.1111/liv.13584] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
50 Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurologica Scandinavica 2008;118:281-90. [DOI: 10.1111/j.1600-0404.2008.01009.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
51 Kuzu UB, Öztaş E, Turhan N, Saygili F, Suna N, Yildiz H, Kaplan M, Akpinar MY, Akdoğan M, Kaçar S, Kiliç ZM, Köksal AŞ, Ödemiş B, Kayaçetin E. Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis. Hepatol Res 2016;46:277-91. [PMID: 25926402 DOI: 10.1111/hepr.12530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
52 Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: accuracy of diagnosis in published reports. Annals of Hepatology 2014;13:248-55. [DOI: 10.1016/s1665-2681(19)30888-9] [Cited by in Crossref: 41] [Article Influence: 5.9] [Reference Citation Analysis]
53 Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM, Hamid S, Tan SS, Philips CA, George J, Jafri W, Sarin SK; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int 2021;15:258-82. [PMID: 33641080 DOI: 10.1007/s12072-021-10144-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
54 Marschall H, Wagner M, Zollner G, Trauner M. Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. Mol Pharmaceutics 2007;4:895-910. [DOI: 10.1021/mp060133c] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
55 Zhang X, Ouyang J, Thung SN. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis. 2013;17:547-564, vii-viii. [PMID: 24099017 DOI: 10.1016/j.cld.2013.07.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
56 Teschke R, Frenzel C. Drug induced liver injury: do we still need a routine liver biopsy for diagnosis today? Annals of Hepatology 2014;13:121-6. [DOI: 10.1016/s1665-2681(19)30913-5] [Cited by in Crossref: 18] [Article Influence: 2.6] [Reference Citation Analysis]
57 Amacher DE. Female gender as a susceptibility factor for drug-induced liver injury. Hum Exp Toxicol. 2014;33:928-939. [PMID: 24299907 DOI: 10.1177/0960327113512860] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
58 Dara L, Liu Z, Kaplowitz N. Pathogenesis of Idiosyncratic Drug Induced Liver Injury. Liver Pathophysiology. Elsevier; 2017. pp. 87-100. [DOI: 10.1016/b978-0-12-804274-8.00005-9] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
59 Yang J, Yu YL, Jin Y, Zhang Y, Zheng CQ. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J Gastroenterol 2016; 22(33): 7579-7586 [PMID: 27672278 DOI: 10.3748/wjg.v22.i33.7579] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Tian QJ, Zhao XY, Wang Y, Wee A, Soon GST, Gouw ASH, Li M, Yang RY, Wang L, Wang QY, Duan WJ, Wang Y, Wang XM, Kong YY, Ou XJ, You H, Jia JD. Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury. Mod Pathol 2019;32:1795-805. [PMID: 31300804 DOI: 10.1038/s41379-019-0314-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Hou F, Zeng Z, Wang G. Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes. Cell Biochem Biophys 2012;64:77-83. [DOI: 10.1007/s12013-012-9373-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
62 Weil JG, Bains C, Linke A, Clark DW, Stirnadel HA, Hunt CM. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Regulatory Toxicology and Pharmacology 2008;52:85-8. [DOI: 10.1016/j.yrtph.2008.06.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
63 Yusuf D, Christy J, Owen D, Ho M, Li D, Fishman MJ. A case report of nifedipine-induced hepatitis with jaundice. BMC Res Notes. 2018;11:228. [PMID: 29615102 DOI: 10.1186/s13104-018-3322-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
64 Lin J, Moore D, Hockey B, Di Lernia R, Gorelik A, Liew D, Nicoll A. Drug-induced hepatotoxicity: incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients. Liver Int 2014;34:576-82. [PMID: 23944929 DOI: 10.1111/liv.12278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
65 Watkins PB. Biomarkers for Drug-Induced Liver Injury. Drug-Induced Liver Disease. Elsevier; 2013. pp. 275-86. [DOI: 10.1016/b978-0-12-387817-5.00017-0] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
66 Verma S, Kaplowitz N. Hepatotoxicity of Antitubercular Drugs. Drug-Induced Liver Disease. Elsevier; 2013. pp. 483-504. [DOI: 10.1016/b978-0-12-387817-5.00027-3] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
67 Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. World J Gastroenterol 2007; 13(3): 329-340 [PMID: 17230599 DOI: 10.3748/wjg.v13.i3.329] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 66] [Article Influence: 6.2] [Reference Citation Analysis]
68 Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14:6774-6785. [PMID: 19058303 DOI: 10.3748/wig.14.6774] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
69 Björnsson ES. Drug-induced liver injury due to antibiotics. Scand J Gastroenterol 2017;52:617-23. [PMID: 28276834 DOI: 10.1080/00365521.2017.1291719] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
70 Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008;48:1175-1183. [PMID: 18798340 DOI: 10.1002/hep.22442] [Cited by in Crossref: 126] [Cited by in F6Publishing: 115] [Article Influence: 9.7] [Reference Citation Analysis]
71 Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914-928. [PMID: 24389305 DOI: 10.1053/j.gastro.2013.12.032] [Cited by in Crossref: 147] [Cited by in F6Publishing: 131] [Article Influence: 18.4] [Reference Citation Analysis]
72 Wang Q, Huang A, Wang JB, Zou Z. Chronic Drug-Induced Liver Injury: Updates and Future Challenges. Front Pharmacol 2021;12:627133. [PMID: 33762948 DOI: 10.3389/fphar.2021.627133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Robles-Diaz M, Garcia-Cortes M, Medina-Caliz I, Gonzalez-Jimenez A, Gonzalez-Grande R, Navarro JM, Castiella A, Zapata EM, Romero-Gomez M, Blanco S, Soriano G, Hidalgo R, Ortega-Torres M, Clavijo E, Bermudez-Ruiz PM, Lucena MI, Andrade RJ; Spanish DILI Registry., Faster Evidence-based Translation (SAFE-T) Consortium. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int 2015;35:2474-82. [PMID: 25809419 DOI: 10.1111/liv.12834] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
74 Mattes W, Davis K, Fabian E, Greenhaw J, Herold M, Looser R, Mellert W, Groeters S, Marxfeld H, Moeller N. Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma. Toxicol Lett. 2014;230:467-478. [PMID: 25086301 DOI: 10.1016/j.toxlet.2014.07.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
75 Jüngst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, Lammert F. Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest. 2013;43:1069-1083. [PMID: 23927644 DOI: 10.1111/eci.12128] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
76 Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015;17:14. [PMID: 26712744 DOI: 10.3390/ijms17010014] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
77 Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: Key regulators of T-cell-mediated drug hypersensitivity. HLA 2018;91:3-16. [PMID: 29171940 DOI: 10.1111/tan.13183] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 20.0] [Reference Citation Analysis]
78 Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf. 2012;35:1091-1097. [PMID: 22897137 DOI: 10.2165/11631960-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
79 Vilas-Boas F, Gonçalves R, Sobrinho Simões M, Lopes J, Macedo G. Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. Gastroenterol Hepatol 2012;35:560-6. [PMID: 22789729 DOI: 10.1016/j.gastrohep.2012.05.007] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
80 Teschke R. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.Expert Opin Drug Metab Toxicol. 2018;14:1169-1187. [PMID: 30354694 DOI: 10.1080/17425255.2018.1539077] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
81 Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol. 2009;50:111-117. [PMID: 19010564 DOI: 10.1016/j.jhep.2008.08.017] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 5.3] [Reference Citation Analysis]
82 Andrade RJ, Robles‐díaz M. Diagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice. Liver Int 2019;40:6-17. [DOI: 10.1111/liv.14271] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
83 Björnsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007;26:79-85. [PMID: 17555424 DOI: 10.1111/j.1365-2036.2007.03355.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
84 Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, Freston JW. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33:503-522. [PMID: 20486732 DOI: 10.2165/11535340-000000000-00000] [Cited by in Crossref: 112] [Cited by in F6Publishing: 94] [Article Influence: 10.2] [Reference Citation Analysis]
85 Merli M, Bragazzi MC, Giubilo F, Callea F, Attili AF, Alvaro D. Atorvastatin-Induced Prolonged Cholestasis with Bile Duct Damage: . Clinical Drug Investigation 2010;30:205-9. [DOI: 10.2165/11531660-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
86 Ghabril M, Chalasani N, Björnsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol 2010;26:222-6. [PMID: 20186054 DOI: 10.1097/MOG.0b013e3283383c7c] [Cited by in Crossref: 82] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
87 Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55-68. [PMID: 19132805 DOI: 10.2165/00002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr Opin Gastroenterol 2007;23:244-54. [PMID: 17414839 DOI: 10.1097/MOG.0b013e3280b17dfb] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
89 Stine JG, Chalasani NP. Drug Hepatotoxicity: Environmental Factors. Clin Liver Dis. 2017;21:103-113. [PMID: 27842766 DOI: 10.1016/j.cld.2016.08.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
90 Dalal KK, Holdbrook T, Peikin SR. Ayurvedic drug induced liver injury. World J Hepatol 2017; 9(31): 1205-1209 [PMID: 29152040 DOI: 10.4254/wjh.v9.i31.1205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
91 Hunt CM, Papay JI, Edwards RI, Theodore D, Alpers DH, Dollery C, Debruin TW, Adkison KK, Stirnadel HA, Gibbs TG. Monitoring liver safety in drug development: the GSK experience. Regul Toxicol Pharmacol 2007;49:90-100. [PMID: 17655994 DOI: 10.1016/j.yrtph.2007.06.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
92 Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14:6774-6785. [PMID: 19058303 DOI: 10.4748/wjg.14.6774] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf. 2014;13:67-81. [PMID: 24073714 DOI: 10.1517/14740338.2013.828032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
94 Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. Medicines (Basel) 2020;7:E62. [PMID: 33003400 DOI: 10.3390/medicines7100062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
95 Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol. 2012;18:249-257. [PMID: 23091804 DOI: 10.3350/cmh.2012.18.3.249] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 8.0] [Reference Citation Analysis]
96 Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, Hu P, Hu XQ, Jia JD, Lai RT, Li DL, Liu YX, Lu LG, Ma SW, Ma X, Nan YM, Ren H, Shen T, Wang H, Wang JY, Wang TL, Wang XJ, Wei L, Xie Q, Xie W, Yang CQ, Yang DL, Yu YY, Zeng MD, Zhang L, Zhao XY, Zhuang H;  Drug-induced Liver Injury (DILI) Study Group;  Chinese Society of Hepatology (CSH);  Chinese Medical Association (CMA). CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221-241. [PMID: 28405790 DOI: 10.1007/s12072-017-9793-2] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 23.0] [Reference Citation Analysis]
97 Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806-815. [PMID: 21544079 DOI: 10.1038/clpt.2011.58] [Cited by in Crossref: 495] [Cited by in F6Publishing: 444] [Article Influence: 49.5] [Reference Citation Analysis]
98 Shapiro MA, Lewis JH. Causality Assessment of Drug-Induced Hepatotoxicity: Promises and Pitfalls. Clinics in Liver Disease 2007;11:477-505. [DOI: 10.1016/j.cld.2007.06.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 6.5] [Reference Citation Analysis]
99 Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA; DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014;147:96-108.e4. [PMID: 24681128 DOI: 10.1053/j.gastro.2014.03.045] [Cited by in Crossref: 128] [Cited by in F6Publishing: 110] [Article Influence: 18.3] [Reference Citation Analysis]
100 Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55-68. [PMID: 19132805 DOI: 10.2165/00002018-200932010-00005] [Cited by in Crossref: 286] [Cited by in F6Publishing: 256] [Article Influence: 23.8] [Reference Citation Analysis]
101 Lucena MI, Cohen H, Hernández N, Bessone F, Dacoll C, Stephens C, Borraz Y, Ulzurrun E, Bruguera M, Andrade RJ. Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad. Gastroenterología y Hepatología 2011;34:361-8. [DOI: 10.1016/j.gastrohep.2011.01.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
102 Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338-347. [PMID: 21570397 DOI: 10.1053/j.gastro.2011.04.001] [Cited by in Crossref: 312] [Cited by in F6Publishing: 260] [Article Influence: 31.2] [Reference Citation Analysis]
103 Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB; DILIN Investigators. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.Am J Gastroenterol. 2015;110:1450-1459. [PMID: 26346867 DOI: 10.1038/ajg.2015.283] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 10.7] [Reference Citation Analysis]
104 Andrade RJ, Lucena MI. Drug Induced Liver Disease: Mechanisms and Diagnosis. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 771-86. [DOI: 10.1002/9781444314403.ch47] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, Papanti D, Schifano F. 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports. Curr Neuropharmacol 2020;18:809-37. [PMID: 31933443 DOI: 10.2174/1570159X18666200110121333] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
106 Santra S, Bishnu D, Dhali GK, Santra A, Chowdhury A. Expression of type I collagen in response to Isoniazid exposure is indirect and is facilitated by collateral induction of cytochrome P450 2E1: An in-vitro study. PLoS One 2020;15:e0236992. [PMID: 32735603 DOI: 10.1371/journal.pone.0236992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Xu HM, Chen Y, Xu J, Zhou Q. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol 2012; 18(41): 5972-5978 [PMID: 23139615 DOI: 10.3748/wjg.v18.i41.5972] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
108 Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Regul Toxicol Pharmacol. 2011;59:1-7. [PMID: 20854865 DOI: 10.1016/j.yrtph.2010.09.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
109 Woo HJ, Kim HY, Choi ES, Cho YH, Kim Y, Lee JH, Jang E. Drug-induced liver injury: A 2-year retrospective study of 1169 hospitalized patients in a single medical center. Phytomedicine. 2015;22:1201-1205. [PMID: 26598920 DOI: 10.1016/j.phymed.2015.10.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
110 Kuna L, Bozic I, Kizivat T, Bojanic K, Mrso M, Kralj E, Smolic R, Wu GY, Smolic M. Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives. Curr Drug Metab 2018;19:830-8. [PMID: 29788883 DOI: 10.2174/1389200219666180523095355] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
111 Zhu W, Wang L, Zhao X, Wang T, Shi X, Ou X, Wang Y, Wang X, Duan W, Wang Q, Jia J, Ma H. Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug‐induced liver injury. Hepatol Res 2020;50:224-32. [DOI: 10.1111/hepr.13435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
112 Zhang Z, Li S, Zhang Z, Yu K, Duan X, Long L, Zhang S, Jiang M, Liu O. Clinical Features, Risk Factors, and Prognostic Markers of Drug-Induced Liver Injury in Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Indian J Dermatol 2020;65:274-8. [PMID: 32831367 DOI: 10.4103/ijd.IJD_217_19] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Hita EO, García JA, Gonzalez JC, Molina AA, Cordero MA, Escobar JS, Ruiz-Extremera A. Amoxicillin-clavulanic acid hepatotoxicity in children. J Pediatr Gastroenterol Nutr 2012;55:663-7. [PMID: 22710999 DOI: 10.1097/MPG.0b013e318263ebfa] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
114 Ogese MO, Faulkner L, Jenkins RE, French NS, Copple IM, Antoine DJ, Elmasry M, Malik H, Goldring CE, Park BK, Betts CJ, Naisbitt DJ. Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells. Toxicological Sciences 2017;158:76-89. [DOI: 10.1093/toxsci/kfx069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
115 Chopra S, Saxena R. Drug-Induced Liver Injury—Perspectives from Pathology. Curr Pharmacol Rep 2018;4:182-92. [DOI: 10.1007/s40495-018-0136-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Mattes WB, Kamp HG, Fabian E, Herold M, Krennrich G, Looser R, Mellert W, Prokoudine A, Strauss V, van Ravenzwaay B, Walk T, Naraoka H, Omura K, Schuppe-Koistinen I, Nadanaciva S, Bush ED, Moeller N, Ruiz-Noppinger P, Piccoli SP. Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling. Biomed Res Int 2013;2013:202497. [PMID: 23762827 DOI: 10.1155/2013/202497] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
117 Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O, Motola D, Dusi G, Caputi AP. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007;60:121-126. [PMID: 17449881 DOI: 10.1093/jac/dkm111] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
118 Sandhu N, Navarro V. Drug-Induced Liver Injury in GI Practice. Hepatol Commun. 2020;4:631-645. [PMID: 32363315 DOI: 10.1002/hep4.1503] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
119 Pedraza L, Laosa O, Rodríguez-Mañas L, Gutiérrez-Romero DF, Frías J, Carnicero JA, Ramírez E. Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. Front Pharmacol 2020;11:600255. [PMID: 33613279 DOI: 10.3389/fphar.2020.600255] [Reference Citation Analysis]
120 Teschke R, Schulze J. Suspected Herbal Hepatotoxicity: Requirements for Appropriate Causality Assessment by the US Pharmacopeia. Drug Saf 2012;35:1091-7. [DOI: 10.1007/bf03261996] [Cited by in Crossref: 28] [Article Influence: 3.1] [Reference Citation Analysis]
121 Shen X, Yuan Z, Mei J, Zhang Z, Guo J, Wu Z, Wu J, Zhang H, Pan J, Huang W. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law. Drug Saf. 2014;37:43-51. [PMID: 24203912 DOI: 10.1007/s40264-013-0119-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
122 Xiao X, Tang J, Mao Y, Li X, Wang J, Liu C, Sun K, Ye Y, Zou Z, Peng C, Yang L, Guo Y, Bai Z, He T, Jing J, Li F, An N. Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China Food and Drug Administration. Acta Pharm Sin B 2019;9:648-58. [PMID: 31193760 DOI: 10.1016/j.apsb.2018.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
123 Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958-976. [PMID: 21327704 DOI: 10.1007/s10620-011-1611-4] [Cited by in Crossref: 152] [Cited by in F6Publishing: 118] [Article Influence: 15.2] [Reference Citation Analysis]
124 Mohamed AK, Magdy M. Caspase 3 role and immunohistochemical expression in assessment of apoptosis as a feature of H1N1 vaccine-caused Drug-Induced Liver Injury (DILI). Electron Physician 2017;9:4261-73. [PMID: 28713494 DOI: 10.19082/4261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. NMR Biomed 2013;26:1258-70. [PMID: 23564602 DOI: 10.1002/nbm.2946] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
126 Riebensahm C, Ka D, Sow A, Semmo N, Wandeler G. A closer look at the spectrum of drug-induced liver injury in sub-Saharan Africa. Expert Rev Clin Pharmacol 2019;12:875-83. [PMID: 31269818 DOI: 10.1080/17512433.2019.1638251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009;54:84-90. [PMID: 19303041 DOI: 10.1016/j.yrtph.2009.03.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
128 Zimmer V, Lammert F. Role of genetics in diagnosis and therapy of acquired liver disease. Molecular Aspects of Medicine 2014;37:15-34. [DOI: 10.1016/j.mam.2013.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
129 Nicoll A, Moore D, Njoku D, Hockey B. Repeated exposure to modern volatile anaesthetics may cause chronic hepatitis as well as acute liver injury. BMJ Case Rep 2012;2012:bcr2012006543. [PMID: 23131606 DOI: 10.1136/bcr-2012-006543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
130 Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update.Arch Toxicol. 2020;94:3381-3407. [PMID: 32852569 DOI: 10.1007/s00204-020-02885-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
131 Shin J, Hunt CM, Suzuki A, Papay JI, Beach KJ, Cheetham TC. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data: DRUG-ASSOCIATED LIVER INJURY. Pharmacoepidemiol Drug Saf 2013;22:190-8. [DOI: 10.1002/pds.3388] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
132 Van Bambeke F, Tulkens PM. Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin: Comparison with Other Fluoroquinolones and Other Antibacterial Classes. Drug Safety 2009;32:359-78. [DOI: 10.2165/00002018-200932050-00001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
133 Salvo F, De Sarro A, Caputi AP, Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf 2009;8:111-8. [PMID: 19236222 DOI: 10.1517/14740330802527984] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
134 Mizrahi M, Adar T, Lalazar G, Nachman D, El Haj M, Ben Ya'acov A, Lichtenstein Y, Shabat Y, Kanovich D, Zolotarov L, Ilan Y. Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for "Safer Drug" Formulation that Prevents Drug-induced Liver Injury. J Clin Transl Hepatol 2018;6:127-34. [PMID: 29951356 DOI: 10.14218/JCTH.2017.00071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Rathi C, Pipaliya N, Patel R, Ingle M, Phadke A, Sawant P. Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality. Annals of Hepatology 2017;16:442-50. [DOI: 10.5604/01.3001.0009.8600] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
136 Ahmad J, Odin JA. Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity. Clin Liver Dis 2017;21:55-72. [PMID: 27842775 DOI: 10.1016/j.cld.2016.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
137 Biswas A, Santra S, Bishnu D, Dhali GK, Chowdhury A, Santra A. Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism. Int J Hepatol 2020;2020:6987295. [PMID: 32373368 DOI: 10.1155/2020/6987295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
138 Brauer R, Douglas I, Garcia Rodriguez LA, Downey G, Huerta C, de Abajo F, Bate A, Feudjo Tepie M, de Groot MC, Schlienger R, Reynolds R, Smeeth L, Klungel O, Ruigómez A. Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. Pharmacoepidemiol Drug Saf 2016;25 Suppl 1:29-38. [PMID: 27038354 DOI: 10.1002/pds.3861] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
139 Li J, Zhang J, Xu X, Fang W, Qu S, Jin F, Zhou J, Han X, Raza HK, Li X, Mao Y. Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database. Expert Rev Clin Pharmacol 2021;:1-8. [PMID: 34521298 DOI: 10.1080/17512433.2021.1981859] [Reference Citation Analysis]
140 Spraggs CF, Xu C, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics 2013;14:541-54. [DOI: 10.2217/pgs.13.24] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
141 Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-53. [PMID: 19689281 DOI: 10.2174/092986709788803097] [Cited by in Crossref: 231] [Cited by in F6Publishing: 202] [Article Influence: 19.3] [Reference Citation Analysis]
142 Marignani M, Fonzo MD, Begini P, Gigante E, Deli I, Pellicelli AM, Gallina S, Santis E, Fave GD, Cox MC. ‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas. World J Gastrointest Pharmacol Ther 2012; 3(2): 21-28 [PMID: 22577616 DOI: 10.4292/wjgpt.v3.i2.21] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
143 Ichai P, Samuel D. Epidemiology of liver failure. Clinics and Research in Hepatology and Gastroenterology 2011;35:610-7. [DOI: 10.1016/j.clinre.2011.03.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
144 Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, Lin L, Xie WF. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury: Corticosteroid use in drug-induced liver injury. Journal of Digestive Diseases 2016;17:618-27. [DOI: 10.1111/1751-2980.12383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
145 Hoofnagle JH. LiverTox. Drug-Induced Liver Disease. Elsevier; 2013. pp. 725-32. [DOI: 10.1016/b978-0-12-387817-5.00040-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Yeong TT, Lim KH, Goubet S, Parnell N, Verma S. Natural history and outcomes in drug-induced autoimmune hepatitis. Hepatol Res 2016;46:E79-88. [PMID: 25943838 DOI: 10.1111/hepr.12532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
147 Caines A, Moonka D. Drug Hepatotoxicity. Clinics in Liver Disease 2020;24:25-35. [DOI: 10.1016/j.cld.2019.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
148 Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 2015;30:775-81. [PMID: 25416628 DOI: 10.1007/s00467-014-2990-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
149 Bhamidimarri KR, Schiff E. Drug-induced cholestasis. Clin Liver Dis. 2013;17:519-531, vii. [PMID: 24099015 DOI: 10.1016/j.cld.2013.07.015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
150 Bessone F. Predicting fatalities in serious idiosyncratic drug-induced liver injury-a matter of choosing the best Hy's law. Transl Gastroenterol Hepatol 2017;2:112. [PMID: 29354769 DOI: 10.21037/tgh.2017.12.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
151 Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O. A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding. Drug Metab Dispos 2009;37:1970-7. [DOI: 10.1124/dmd.109.027797] [Cited by in Crossref: 188] [Cited by in F6Publishing: 145] [Article Influence: 15.7] [Reference Citation Analysis]
152 Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez-Escolá C, Luque-Ramírez M, Fernandez-Rodriguez E, Paniagua AE, Quinteiro C, Casanueva FF. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab. 2010;95:2147-2154. [PMID: 20207827 DOI: 10.1210/jc.2009-2547] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
153 Smith A, Dillon J. Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies. BMJ Case Rep. 2009;2009:bcr02.2009.1603. [PMID: 21887162 DOI: 10.1136/bcr.02.2009.1603] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
154 Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14(44): 6774-6785 [PMID: 19058303 DOI: 10.3748/wjg.14.6774] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 90] [Article Influence: 8.0] [Reference Citation Analysis]
155 Saithanyamurthi H, Faust AJ. Drug-Induced Liver Disease: Clinical Course. Clin Liver Dis 2017;21:21-34. [PMID: 27842773 DOI: 10.1016/j.cld.2016.08.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
156 Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246-2259. [PMID: 20394749 DOI: 10.1053/j.gastro.2010.04.001] [Cited by in Crossref: 202] [Cited by in F6Publishing: 176] [Article Influence: 18.4] [Reference Citation Analysis]
157 Xing M, Zhai L, Li J, Li Q, Gao M, Wen J, Xu Z. Assessment of cholestasis in drug-induced liver injury by different methods. Medicine (Baltimore) 2019;98:e14399. [PMID: 30732184 DOI: 10.1097/MD.0000000000014399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Yang X, Schnackenberg LK, Shi Q, Salminen WF. Hepatic toxicity biomarkers. Biomarkers in Toxicology. Elsevier; 2014. pp. 241-59. [DOI: 10.1016/b978-0-12-404630-6.00013-0] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
159 Deng X, Luyendyk JP, Ganey PE, Roth RA. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 2009;61:262-82. [PMID: 19805476 DOI: 10.1124/pr.109.001727] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 8.5] [Reference Citation Analysis]
160 Sanabria-Cabrera J, Medina-Cáliz I, Stankevičiūtė S, Rodríguez-Nicolás A, Almarza-Torres M, Lucena MI, Andrade RJ. Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. Curr Pharm Des 2019;25:3855-71. [PMID: 31696806 DOI: 10.2174/1381612825666191107161912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
161 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel: Chair:., Panel members:., EASL Governing Board representative:. EASL Clinical Practice Guideline: Occupational liver diseases. J Hepatol 2019;71:1022-37. [PMID: 31540728 DOI: 10.1016/j.jhep.2019.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
162 Davern TJ. Drug-induced liver disease. Clin Liver Dis. 2012;16:231-245. [PMID: 22541696 DOI: 10.1016/j.cld.2012.03.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
163 Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci. 2016;17. [PMID: 27187363 DOI: 10.3390/ijms17050714] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
164 Isabel Lucena M, García-cortés M, Cueto R, Lopez-duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008;22:141-58. [DOI: 10.1111/j.1472-8206.2008.00566.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
165 Maddur H, Chalasani N. Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep. 2011;13:65-71. [PMID: 21049293 DOI: 10.1007/s11894-010-0154-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
166 Parikh ND, Levitsky J. Hepatotoxicity and drug interactions in liver transplant candidates and recipients. Clin Liver Dis 2013;17:737-47, x-xi. [PMID: 24099028 DOI: 10.1016/j.cld.2013.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
167 Lucena MI, Andrade RJ, Martínez C, Ulzurrun E, García-Martín E, Borraz Y, Fernández MC, Romero-Gomez M, Castiella A, Planas R, Costa J, Anzola S, Agúndez JA; Spanish Group for the Study of Drug-Induced Liver Disease. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-96. [PMID: 18666253 DOI: 10.1002/hep.22370] [Cited by in Crossref: 147] [Cited by in F6Publishing: 114] [Article Influence: 11.3] [Reference Citation Analysis]